| abstract |
The invention relates to adamantylacetamide formula (I), their N-oxide forms, pharmaceutically acceptable additive salts and stereochemically isomeric forms, where n is an integer equal to 1; m is an integer equal to 0 or 1; R1 and R2, each independently, represents C1-6 alkyl; or R and R together with the carbon atom to which they are attached, form Cycloalkyl; R3 is an optionally substituted adamantyl of formula (a) or (b); Q is an optionally substituted phenyl, benzothiophenyl, or pyridyl; L is Salkyl. In addition, the invention relates to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as an active ingredient, an effective inhibitory 11β-HSD1 amount of a compound of the invention, a method for preparing it and the use of a compound of the invention for preparing a medicament for treating visceral obesity, insulin sensitivity , type 2 diabetes, hyperlipidemia and hyperphagia. |